Skip to content

A study on efficiacy and safety of telbivudine in interruption of intrauterine infection of hepatitis B virus

A study on efficiacy and safety of telbivudine in interruption of intrauterine infection of hepatitis B virus

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TCC-09000420
Enrollment
Unknown
Registered
2009-05-20
Start date
2007-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine infection 0f hepatitis B virus

Interventions

Control Group:no
telbivudine group:telbivudine 600mg/day, oral

Sponsors

The Nangjing Second Hospital Affiliated Southeast Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Pregnant women from 24 to 32 weeks of gestation; 2. HBsAg and HBeAg of blood serum have been positive for more than 6 months; 3. HBV-DNA quantitation of blood plasma > 1,000,000 copy/ml; 4. Alanine aminotransferase is normal or abnormal in 2 to10 times higher than top limit of normal value; 5. Compensatory liver disease that PT prolong not more than 3 minutes, TBIL not more than 2 times of normal value; albumin and creatinine are normal; 6. To be willing to assign informed consent and abide by treatment scheme as well as follow-up plan; 7. HBsAg, HBeAg, HBV DNA of her husband are all negative.

Exclusion criteria

Exclusion criteria: 1. B-type sonography find fetal abnormal or has history of threatened abortion; 2. One of antibodies of heptitis A, C, D virus and human immunodeficiency virus is positive; 3. Severe malnutrition, kidney disease, diabetes etc diseases; 4. Amphibiotic apparent cardiovascular disease or electrocardiogram shows obvious abnormality; 5. Has ever received any antiviral therapy with interferon, immunomodulator, nucleoside analog, etc al in 6 months before the study; 6. The patients who are thought to be unfit for being selected to the study or have the other factors that may have influence on participation of patients or accomplishment of the study; 7. With pathological changes of muscles or high creatine kinase; 8. With any complication in pregnancy which may lead to abnormal Hepatic function such as eclamptism or eclampsismy or intrahepatic cholestasis of pregnancy.

Design outcomes

Primary

MeasureTime frame
HBV-DNA;HBV-m, HBsAb, HBeA;

Secondary

MeasureTime frame
Liver function: ALT, AST, TB, ALB;WBC and Plt concentration;CK;BUN and Cr concentration;

Countries

China

Contacts

Public ContactMinMin YU
yuminmin324@126.com+86 0 13952040383

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026